The flickering fluorescent lights of a federal courthouse hallway hummed, casting long shadows as a lawyer, tie askew, gathered his papers, the scent of stale coffee and desperation thick in the air.
Forget the slick PR releases and the shiny new AI tools promising to revolutionize legal practice. Right now, the real action, the kind that makes careers and breaks them, is happening in the dusty corners of bureaucratic procedure. And here we are, digging through another mess at the United States Patent and Trademark Office (USPTO), a place that seems to have a recurring appointment with its own worst practices. This time, it’s about the return of the “secret examination docket” – a concept so legally dubious, you’d think they’d have learned their lesson.
Remember SAWS? The Sensitive Application Warning System? Operated from 1994 to 2015, it was the USPTO’s own little black box for patent applications deemed… well, “sensitive.” They spun it as quality control, a way to give extra scrutiny to high-impact inventions. What it actually was, according to plenty of folks who got caught in its web, was a black hole where promising patents went to die, unannounced and unceremoniously. Applicants had no clue their inventions were being held hostage, stuck in a procedural purgatory that flat-out ignored federal law. Federal law, mind you, that demands transparency. 35 U.S.C. § 132 and 37 C.F.R. § 1.2 are pretty clear: if you’re going to reject something, you better have a written reason. Everything is supposed to be on the written record. But SAWS? SAWS was the antithesis of that. It was a ghost in the machine, a whisper campaign against your patent rights.
The Ghost of SAWS Past Looms Large
Now, almost a decade after SAWS officially bit the dust, the USPTO seems to be dabbling in a spiritual successor. This latest kerfuffle is brewing in Morinville v. USPTO, where a joint status report is aiming to pry open the lid on what looks suspiciously like another shadow docket. The core of the issue? The Office of Patent Quality Assurance (OPQA) has been running what they’re calling the “Large Patent Family Review Program.” Ostensibly, this program, which ran from November 2021 to May 2025, was about improving patent quality by analyzing large patent families and providing educational insights. MPEP 1308.03 says these reviews are for educational purposes, not to influence allowance decisions. If an error is found, the MPEP explicitly states the case should be reopened, and applicants notified.
But here’s the kicker, the part that makes my cynicism gland ache: IPWatchdog’s reporting suggests this “review” has quietly morphed into something far more sinister. When OPQA found issues before an application was granted – issues that should trigger notification and reopening – the applications were apparently just sent back to examiners. No formal reopening, no heads-up to the applicant. Just a secret nudge from OPQA, a whispered suggestion to the examiner that maybe this patent isn’t so hot after all. And wouldn’t you know it, the allowance decision gets quietly reversed. Sounds a lot like SAWS to me. Who’s actually benefiting here? Certainly not the inventors or the companies trying to innovate.
It’s a classic bureaucratic maneuver: rebrand the same old bad practice with a new, shiny name and a veneer of good intentions. “Quality assurance.” “Educational tool.” Please. The real game is clearly about control and avoiding the messy work of actual, transparent due process. And let’s be honest, examiners don’t want trouble. If OPQA flags something, examiners are incentivized — or perhaps, more accurately, intimidated — to comply. What’s a little due process when you can avoid an unpleasant note on your performance review?
“The government’s narrative cannot be allowed to rest on the testimony of a witness who by her own admission is not competent because she admitted to having no firsthand knowledge.”
This quote, from the heart of the Morinville filing, perfectly encapsulates the problem. When the system itself is built on opacity and the testimony of those who admit to lacking direct knowledge, how can anyone trust the outcome? It’s not just about SAWS or the OPQA program; it’s about a systemic disregard for fundamental fairness. The USPTO seems to be operating under the misguided notion that they can conduct hidden reviews and manipulate the patent process without consequence, all while touting their commitment to innovation. It’s a contradiction that’s as old as Silicon Valley itself, and frankly, it’s getting tiresome.
A Question of Accountability
This isn’t just about the USPTO; it’s a microcosm of a larger trend. In the race to appear efficient and in control, government agencies and corporations alike are tempted by the allure of the “secret docket,” the informal channel, the off-the-record conversation that dictates outcomes. But in the legal and patent world, where rights are adjudicated and fortunes are made or lost, such practices are an affront to the very concept of justice. The Morinville case, and the renewed focus on SAWS-like behaviors, is a crucial reminder that sunlight is the best disinfectant. And right now, the USPTO’s back rooms are looking awfully dim.
Who is making money here? Not the applicants whose patents are being quietly killed. Not the examiners who are being pressured into questionable decisions. Likely, it’s the bureaucrats who get to feel important managing these secret programs, and perhaps the lawyers who will inevitably be paid to sue over these opaque practices down the line. It’s a self-perpetuating cycle of dysfunction.
Is the USPTO’s New ‘Quality Review’ Just SAWS in Disguise?
The evidence certainly points in that direction. The original SAWS program operated from 1994 to 2015, and its function was to flag “sensitive” applications for extra review, often without the applicant’s knowledge. The current allegations surrounding the OPQA’s Large Patent Family Review Program describe a strikingly similar process: applications flagged internally for issues are reportedly sent back to examiners for reconsideration, leading to altered allowance decisions, all while the applicant remains in the dark. This bypasses the legal requirement for open communication and written records in patent prosecution. The MPEP itself outlines procedures for notification and reopening of cases when errors are found, procedures that seem to be circumvented in this alleged OPQA program.
Why Does This Matter for Innovators?
For inventors and companies seeking patent protection, these secret dockets represent a fundamental threat to their intellectual property rights and business strategies. When patent applications are subjected to undisclosed reviews and internal directives, the process loses its predictability and fairness. Applicants can’t adequately respond to concerns they don’t know exist, potentially leading to the unjustified rejection or significant delay of valuable patents. This breeds an environment of uncertainty, discouraging innovation and investment, as companies can no longer be confident in the integrity of the patent system. It’s a step backward for transparency and a direct hit to the bedrock of intellectual property law.
🧬 Related Insights
- Read more: Intelligence Explosion Looms? Experts Divided on Timeline
- Read more: Anthropic’s Back-to-Back Leaks Hand Rivals Claude Code’s Blueprint
Frequently Asked Questions
What was the SAWS program at the USPTO? SAWS, the Sensitive Application Warning System, was an internal USPTO program from 1994-2015 that flagged certain patent applications for elevated oversight and additional review, often without notifying the applicant.
What is the ‘secret examination docket’ at the USPTO? It refers to internal USPTO processes or programs that review patent applications outside of the standard, transparent prosecution process, potentially affecting allowance decisions without the applicant’s knowledge or input, which is contrary to federal law.
Could the new OPQA program lead to more patent litigation? Yes, if these allegations prove true and patent applicants are indeed being unfairly prejudiced by undisclosed reviews, it could certainly lead to increased litigation as parties seek to challenge allegedly flawed or improperly handled patent decisions.
